Endologix to Participate in Two Investor Conferences in March

IRVINE, Calif. -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate at two investor conferences in March. The first conference is the 26th Annual ROTH Conference in Dana Point, CA.

The second conference is the BTIG Inaugural Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference in Snowbird, UT. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.

An audio webcast of the Company’s presentation at the 26th Annual ROTH Conference will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix’s website at www.endologix.com.